Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) Interest & Investment Income (2020 - 2025)

Xeris Biopharma Holdings' Interest & Investment Income history spans 6 years, with the latest figure at $1.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Interest & Investment Income rose 60.55% year-over-year to $1.5 million, compared with a TTM value of $4.7 million through Dec 2025, down 10.88%, and an annual FY2025 reading of $4.7 million, down 10.88% over the prior year.
  • Interest & Investment Income for Q4 2025 was $1.5 million at Xeris Biopharma Holdings, up from $1.2 million in the prior quarter.
  • The five-year high for Interest & Investment Income was $1.9 million in Q1 2024, with the low at $66000.0 in Q3 2021.
  • Average Interest & Investment Income over 5 years is $885250.0, with a median of $1.1 million recorded in 2023.
  • Year-over-year, Interest & Investment Income plummeted 96.54% in 2021 and then skyrocketed 2532.86% in 2022.
  • Tracing XERS's Interest & Investment Income over 5 years: stood at $70000.0 in 2021, then skyrocketed by 2532.86% to $1.8 million in 2022, then crashed by 39.93% to $1.1 million in 2023, then dropped by 17.8% to $910000.0 in 2024, then skyrocketed by 60.55% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Interest & Investment Income are $1.5 million (Q4 2025), $1.2 million (Q3 2025), and $948000.0 (Q2 2025).